Please find listed some examples of publications from research groups which have used samples accessed through the MCRC Biobank.

  • Somerville, T.D., Wiseman, D.H., Spencer, G.J., Huang, X., Lynch, J.T., Leong, H.S., Williams, E.L., Cheesman, E. and Somervaille, T.C., 2015. Frequent derepression of the mesenchymal transcription factor gene FOXC1 in acute myeloid leukemia. Cancer Cell28(3), pp.329-342.
  • Wiseman, D.H., Struys, E.A., Wilks, D.P., Clark, C.I., Dennis, M.W., Jansen, E.E.W., Salomons, G.S. and Somervaille, T.C., 2015. Direct comparison of quantitative digital PCR and 2-hydroxyglutarate enantiomeric ratio for IDH mutant allele frequency assessment in myeloid malignancy. Leukemia.
  • Wiseman, D.H., Small, H.F., Wilks, D.P., Waddell, I.D., Dennis, M.W., Ogilvie, D.J. and Somervaille, T.C., 2014. Elevated plasma 2‐hydroxyglutarate in acute myeloid leukaemia: association with the IDH1 SNP rs11554137 and severe renal impairment. British journal of haematology,166(1), pp.145-148.
  • Greystoke, B.F., Huang, X., Wilks, D.P., Atkinson, S. and Somervaille, T.C., 2013. Very high frequencies of leukaemia‐initiating cells in precursor T‐acute lymphoblastic leukaemia may be obscured by cryopreservation. British journal of haematology163(4), pp.538-541.
  • Harris, W.J., Huang, X., Lynch, J.T., Spencer, G.J., Hitchin, J.R., Li, Y., Ciceri, F., Blaser, J.G., Greystoke, B.F., Jordan, A.M. and Miller, C.J., 2012. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer cell21(4), pp.473-487.
  • McConnell, J.C., O’Connell, O.V., Brennan, K., Weiping, L., Howe, M., Joseph, L., Knight, D., O’Cualain, R., Lim, Y., Leek, A. and Waddington, R., 2016. Increased peri-ductal collagen micro-organization may contribute to raised mammographic density. Breast Cancer Research18(1), pp.1-17.
  • Girotti, M.R., Gremel, G., Lee, R., Galvani, E., Rothwell, D., Viros, A., Mandal, A.K., Lim, K.H.J., Saturno, G., Furney, S.J. and Baenke, F., 2015. Application of sequencing, liquid biopsies and patient-derived xenografts for personalized medicine in melanoma. Cancer discovery, pp.CD-15.
  • Zelenay, S., van der Veen, A.G., Böttcher, J.P., Snelgrove, K.J., Rogers, N., Acton, S.E., Chakravarty, P., Girotti, M.R., Marais, R., Quezada, S.A. and Sahai, E., 2015. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell162(6), pp.1257-1270.
  • Baenke, F., Chaneton, B., Smith, M., Van Den Broek, N., Hogan, K., Tang, H., Viros, A., Martin, M., Galbraith, L., Girotti, M.R. and Dhomen, N., 2016. Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. Molecular Oncology10(1), pp.73-84.
  • Vizoso, M., Ferreira, H.J., Lopez-Serra, P., Carmona, F.J., Martínez-Cardús, A., Girotti, M.R., Villanueva, A., Guil, S., Moutinho, C., Liz, J. and Portela, A., 2015. Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. Nature medicine21(7), pp.741-750.
  • Girotti, M.R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies, L., Whittaker, S., Saturno, G., Viros, A., Pedersen, M. and Suijkerbuijk, B.M., 2015. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer cell,27(1), pp.85-96.
  • Hirata, E., Girotti, M.R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R. and Sahai, E., 2015. Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling. Cancer cell27(4), pp.574-588.
  • Sherwood, J.L., Corcoran, C., Brown, H., Sharpe, A.D., Musilova, M. and Kohlmann, A., 2016. Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC). PloS one11(2), p.e0150197.
  • Korfi, K., Mandal, A., Furney, S.J., Wiseman, D., Somervaille, T.C.P. and Marais, R., 2015. A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia. Annals of Oncology, p.mdv110.